Appendix 4C — Quarterly

Apr 28, 2018
Posted in: Investor updates

Home » Appendix 4C — Quarterly

Appendix 4C — Quarterly

Apr 28, 2018
Posted in: Investor updates

Imagion Biosystems Limited has announced Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B, for the quarter ended 31 March, 2018.
Read Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B

Positive independent review sets priority path to market for MagSense® Technology

February 5, 2023

Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance

Quarterly Activity Report – Quarter Ending 31 December 2022

January 30, 2023

Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with

Quarterly Activity Report – Quarter Ending 30 September 2022

October 28, 2022

Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Appendix 4C — Quarterly

Appendix 4C — Quarterly

Related Articles

Positive independent review sets priority path to market for MagSense® Technology

Quarterly Activity Report – Quarter Ending 31 December 2022

Quarterly Activity Report – Quarter Ending 30 September 2022

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list